Persian  |  Ahvaz Jundishapur University of Medical Sciences
 
Username
Password
Register
I forgot my password

Journals Office: 2nd floor, School of Medicine Ahvaz Jundishapur University of Medical Sciences, Golestan BLV, Ahvaz - IRAN
Postal Code: 6135715794
Phone: +98-61-33738283
Fax: +98-61-33362537

Home :: Back

Advance Article Search New

Jundishapur J Oncol;2015; March
Article title: Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer

Article File:    Article (PDF) 610 Kb 
Page From: 21 To: 24      
Visit: 1662

Abstract
Background: Gastric cancer remains a major cause of cancer death in Iran despite a significant decreasing incidence in western countries. Surgery alone has not been effective for treatment of locoregional gastric cancer because of the low rate of curative resection and high incidence of local recurrence and distant metastases. Our aim was to determine the resectability of tumor after neoadjuvant chemotherapy. Methods: Fourteen patients with clinical stage III gastric adenocarcinoma that initially seemed to be unresectable by laparoscopy were treated with three cycles of cisplatin 60 mg/m2, 5-Fluorouracil 750 mg/m2 and Epirubicin 50 mg/m2 three weeks before surgery. Results: Thirteen patients were operable for surgery after neoadjuvant chemotherapy (Pvalue= 0.001), while one patient was not operable due to developing distal metastasis. Twelve (85.85%) patients were resectable with pathologic report of R 0 and, one (7.15%) patient was reported R1, (Pvalue= 0.001). Conclusion: this study shows that neoadjuvant chemotherapy improves operability and resectability of the tumor in patients with local advanced gastric adenocarcinoma.

Keywords:
Gastric adenocarcinoma, Neoadjuvant chemotherapy, local advanced, Resectability

Article Authors:
Abdolhassan TalaiezadehFirst Authorahtalaiezadeh@yahoo.com
Amir Jafar ModirgolestanOther Author
Hodjatollah ShahbazianOther Author

References
1-Parkin DM, Bray F. Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness. Eur J Cancer . 2009; (5):756-64.
2-Center for disease control & Prevention Non communicable Deputy, cancer center. Iranian Annual of Nationalancer Registration Report. March 2007; XXVII.
3-Babai M, Mousavi S, Toussy J. Cancer occurrence in old age: Results of a population based cancer registrya in Semnan, I ran. Asian Pac J Cancer P Rev . 2006; (2):191-4.
4-Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, Yazdanb od A, Shokoohi B, Mashayekhi A, Arshi S, Majidpour A, Babaei M, Mosavi A, Mohagheghi MA, Alimohammadian M. Cancer occurrence in Ardabil: results of a population-based cancer registry from I ran. Int J Cancer . 2003; 20;107(1):113-8.
5-Mohagheghi MA, Mosavi-Jarrahi A, Malekzadeh R, Parkin M. Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998-2001. Arch Iran Med . 2009; 12(1):15-23.
6-Smith JL, Luke RE, Douglass HO: Adjuvant therapy of stomach cancer: clinical trial results: In: Wanebo HJ (ed). Surgery for Gastroin testinal Cancer. Philadelphia: J B Lippin Cot , 1997:347-353.
7-Dolores Gallard o-Rin co´n, Luis F. On˜a te-Ocan˜a, and Germa´n Calderillo-Ruiz. Neoadjuvant Chemotherapy with P-ELF (Cisplatin, Etoposide, Leucovorin, 5-Fluorou racil) Followed by Radical Resection in Patients with Initially Unresectable Gastric Adenocarcinoma: A Phase II Stud y. Ann Surgl Oncol. 2000;7(1):45–50.
8-Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Ni colson M, Sca rffe JH, Lofts FJ, Falk SJ, I veson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGI C Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesop hageal cancer. N Engl J Med . 2006; 355(1):11-20.
9-Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, Lauers G, Klimstra D, Huang Y, Saltz L, Quan V, and Brennan M. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. JCO Jun 1, 14(6):1818-28.
10-Cascinu S, Scartozzi M, Labianca R, et al. High Curative Resection Ratewith Weekly, 5 -fluorouracil, epidoxorubicin, 6S-Leucovorin, Glutathione, and Filgrastim in Patients with Locally Advanced, Unresectable Gastric Cancer: A Report From the Italian Group for the Study of Digestive Tract Cancer (GI SCAD). British J Cancer. 2004; 90:1551-1525.
11-Schuhmacher CP, Fink U, Becker K, et al. Neoadjuvant Therapy for Patients with Locally Advanced Gastric Carcinoma with Etoposide, doxorubicin, and cisplatinum. Closing Results after 5 Years of Follow-up. Cancer.2001; 1:918-927.
12-John E. Niederhuber, Neoadjuvant therapy. Ann Surg. 1999; 229(3):309-312.
13-Dolores Gallardo -Rinco´n, Luis F. On˜a te -Ocan ˜a, Germa´n Calderillo -Ruiz. Neoadjuvant Chemo therapy With P-ELF (Cisplatin, Etoposide , Leu covorin, 5-Fluorouracil) Followed by Radical Resection in Patients With Initially Unresectable Gastric Adenocarcinoma: A Phase II Stud y. Annals of Surgical Oncology . 2000, 7(1):45–50.
14-Satoru N, Atsushi NM, Hiroshi Y. Neoadjuvant chemotherapy for Patients with Positive cytology from advanced gastric Cancer. Japanease Journal of Cancer and Chemotherapi. 2006;33 :(12);1774-1776.
15-Scuhmacher CP, Fink U, Becker K, Busch R, Dittler HJ, Mueller J, Siewert JR. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin and cisplatin. Cancer . 2001; 91:918-27.
16-Beckeretal K. Neoadjuvant chemo therapy for patients with locally advanced gastric carcinoma. Cancer . 1999; 85 :1484-9
17-D'Ugo D, Persiani R, Rausei S, Biondi A, Vigori ta V, Bocia S et al. Response to neoadjuvant chemo therapy and ef fects of tumor regression in gastric cancer. Eur J Surg Oncol . 2006; 32(10):1105-9.
18-Crookes P, Leichman CG, Leichman L, et al. Systemic chemotherapy for gastric carcinoma followed by postoperative in traperitoneal therapy: a final report. Cancer. 1997; 79:1767-1775
19-Swisher SG, Holmes EC, Hunt KK, Doty JE, Zinner MJ, Mc Fadden DW. The role of neoadjuvant therapy in surgically resectable esophageal cancer. َArch Surg. 1996; 131:819-824.
20-Nakata B, Chung KH, Muguruma K, et al. Changes in tumor marker levels as a predictor of chemo therapeutic effect in patients with gastric carcinoma. Cancer . 1998; 83: 19-24.
21-Ai-Wen Wu, Jia-Fu Ji. Neoadjuvant chemotherapy for locally advanced gastric cancer: With or without radiation. World J Gostrointest Surg . 2012; 4(2):27–31.




کلیه حقوق این سایت متعلق به دانشگاه علوم پزشکی جندی شاپور اهواز می باشد. استفاده از مطالب این سایت با ذکر نام سایت مجاز می باشد   -   Copyright © 2012
Powered By www.itpco.net
تولید کننده سیستم های تخصصی مدیریت نشریات و همایش ها و مورد تائید وزارت بهداشت درمان و آموزش پزشکی و وزارت ارتباطات و فناوری اطلاعات و